ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

City of Hope

www.cityofhope.org

Breast
Lung
Gastrointestinal
Genitourinary
Leukemia
Lymphoma
Myeloma
Hematologic Malignancies
Head and Neck
General Oncology
Palliative Care
Events

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

By City of Hope FEATURING Jack West

0 views

July 1, 2021

This video was recorded prior to the FDA granting approval to Atezolizumab on 10/15/2021 as ...
read more ↘ adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC
↖ read less

Comments 0

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Lung